These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 25404020

  • 1. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA, Scott LJ.
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [Abstract] [Full Text] [Related]

  • 2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 3. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.
    N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901
    [Abstract] [Full Text] [Related]

  • 4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb 07; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD, Lynch JB.
    Drug Des Devel Ther; 2015 Feb 07; 9():677-82. PubMed ID: 25678771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.
    Lancet Respir Med; 2019 Mar 07; 7(3):249-259. PubMed ID: 30630778
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR, Marathe PA.
    J Assoc Physicians India; 2018 Jul 07; 66(7):72-75. PubMed ID: 31325268
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature.
    Esposito S, Bosis S, Tadolini M, Bianchini S, Migliori GB, Principi N.
    Medicine (Baltimore); 2016 Nov 07; 95(46):e5347. PubMed ID: 27861363
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E, Ferlazzo G, Hewison C, De Azevedo V, Isaakidis P.
    Lancet Infect Dis; 2019 May 07; 19(5):470. PubMed ID: 31034392
    [No Abstract] [Full Text] [Related]

  • 19. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 07; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.